InsidersTradesSigma
Follow the INSMED INCORPORATED stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €25.9bn. The latest transaction was filed on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Martina Flammer. Every trade is accessible without an account.
Analysts rate INSMED INCORPORATED Strong Buy (bullish), based on 22 analysts. Average price target: US$200.18.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
INSMED INCORPORATED 是一家生物制药公司，专注于开发罕见和严重疾病的治疗方法。它专门从事创新疗法的研究和商业化。